Apellis Pharmaceuticals Inc (APLS) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Apellis Pharmaceuticals Inc

NASDAQ | APLS

18.20

USD

+0.04 (+0.22%)

AT CLOSE (AS OF Apr 17, 2025)

$2.3B

MARKET CAP

P/E Ratio

-1.6

EPS

$51

52 Week High

$17

52 Week Low

LIFE SCIENCES

Sector

APLS Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

APLS Technicals

Tags:

APLS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$592M
Total Revenue	$710M
Cost Of Revenue	$118M
Costof Goods And Services Sold	$118M
Operating Income	-$236M
Selling General And Administrative	$501M
Research And Development	$328M
Operating Expenses	$829M
Investment Income Net	-
Net Interest Income	-$28M
Interest Income	$13M
Interest Expense	$40M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.8M
Income Before Tax	-$197M
Income Tax Expense	$1.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$198M
Comprehensive Income Net Of Tax	-
Ebit	-$238M
Ebitda	-$236M
Net Income	-$198M

Revenue & Profitability

Earnings Performance

APLS Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$885M
Total Current Assets	$789M
Cash And Cash Equivalents At Carrying Value	$411M
Cash And Short Term Investments	$411M
Inventory	$81M
Current Net Receivables	-
Total Non Current Assets	$96M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$31M
Other Non Current Assets	-
Total Liabilities	$657M
Total Current Liabilities	$186M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$14M
Total Non Current Liabilities	$471M
Capital Lease Obligations	$17M
Long Term Debt	$453M
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$470M
Other Current Liabilities	$133M
Other Non Current Liabilities	$8M
Total Shareholder Equity	$229M
Treasury Stock	-
Retained Earnings	-$3B
Common Stock	$12K
Common Stock Shares Outstanding	$124M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$88M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$1.8M
Capital Expenditures	$403K
Change In Receivables	-
Change In Inventory	-$11M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$149M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$4.5M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$198M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$592M
Total Revenue	$710M
Cost Of Revenue	$118M
Costof Goods And Services Sold	$118M
Operating Income	-$236M
Selling General And Administrative	$501M
Research And Development	$328M
Operating Expenses	$829M
Investment Income Net	-
Net Interest Income	-$28M
Interest Income	$13M
Interest Expense	$40M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.8M
Income Before Tax	-$197M
Income Tax Expense	$1.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$198M
Comprehensive Income Net Of Tax	-
Ebit	-$238M
Ebitda	-$236M
Net Income	-$198M

APLS News

APLS Profile

Apellis Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

APLS $18.20 (+0.22%) Quote details